Recent advances in the management of multiple myeloma

National Medical Journal of India

Volumn 19, Issue 2, 2006, Pages 80-89

  Kumar, Lalit ^a   Vikram, P ^a   Kochupilla, V ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; METHYLPREDNISOLONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PREDNISOLONE; PROTEASOME INHIBITOR; SERUM ALBUMIN; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AVASCULAR NECROSIS; BACTERIAL INFECTION; BETA 2 MICROGLOBULIN URINE LEVEL; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE DISEASE; BONE MARROW SUPPRESSION; BONE NECROSIS; BRADYCARDIA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONSTIPATION; CYTOGENETICS; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DIURESIS; DRUG ERUPTION; DRUG MEGADOSE; EDEMA; FATIGUE; GENE EXPRESSION PROFILING; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; HYPOTHYROIDISM; KIDNEY DYSFUNCTION; KIDNEY FAILURE; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MOOD DISORDER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYOPATHY; NEUROPATHY; NEUTROPENIA; OSTEOPOROSIS; PATIENT CARE; PERIPHERAL NEUROPATHY; PROGNOSIS; REVIEW; SOMNOLENCE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN THROMBOSIS; BONE MARROW CANCER; DRUG COMBINATION; PATHOPHYSIOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; DEXAMETHASONE; DIPHOSPHONATES; DOXORUBICIN; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 33646823805     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. National Cancer Registry Programme. Two year report of the Population based Cancer registries 1999-2000. New Delhi:Indian Council of Medical Research; 2005.
3. Kumar L, Wadhwa J, Kochupillai V. Multiple myeloma: Recent advances. Indian J Hematol Blood Transf 2001;19:11-16.
4. Advani SH, Soman CS, Talwalkar GV, Iyer YS, Bhatia HM. Multiple myeloma: Review of 231 cases. Indian J Cancer 1978;15:55-61.
5. Hungria VTM, Maiolino A, Martinez G, Coelho EOM, Bittencourt R, Souza CA, et al. South American multiple myeloma study: Epidemiological and clinical characteristics of 751 patients. Haematologica/Hematol J 2005;90 (Suppl 1): 120-1.
6. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
7. Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995;13:251-6.
8. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
9. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
10. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
11. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
12. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
13. Kuehl WM, Bergsagel PL. Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
14. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-64.
15. Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002;17:1921-5.
16. Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003;4:284-92.
17. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1betain the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-202.
18. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005;106:2276-9.
19. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003;122:441-50.
20. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-71.
21. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
22. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage 1 - a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993;50:95-102.
23. Grignani G, Gobbi PG, Formisano R, Pieresca C, Ucci G, Brugnatelli S, et al. A prognostic index for multiple myeloma. Br J Cancer 1996;73:1101-7.
24. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775-9.
25. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-19.
26. Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep 1962;21:87-99.
27. Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109:438-46.
28. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 1992;10:334-42.
29. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992;339:200-5.
30. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-42.
31. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86-9.
32. Monconduit M, Menard JF, Michaux JL, Le Loet X, Bernard JF, Grosbois B, et al. VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myelome (GERM). Br J Haematol 1992;80:199-204.
33. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163-8.
34. Wadhwa J, Kumar L, Kochupillai V. VAD followed by VMCP: An alternative regimen for multiple myeloma. Med Oncol 2002;19:105-8.
35. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
36. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
37. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002;13:1116-19.
38. Rajkumar SV, Blood E, Vesole DH, Shepard R, Greipp PR. A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group. ASCO Annual Meeting Proceedings 2004;23:558 (abstract no. 6508).
39. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9.
40. Abdelkefi A, Torjman L, Ben Romdhane N, Ladeb S, El Omri H, Ben Othman T, et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005;36:193-8.
41. Ghobrial IM, Dispenzieri A, Bundy KL, Gastineau DA, Rajkumar SV, Therneau TM, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003;32:587-92.
42. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2:822-4.
43. Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987;66:55-62.
44. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
45. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
46. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-33.
47. Blade J, Sureda A, Ribera JM, Mediavilla JD, Larafia JG, Palomera L, et al. High dose therapy/autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: Definitive results from PETHEMA after a median follow up of 66 months. Blood 2003;102:42a (abstract no. 137).
48. 2 + TBI 12Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon maintenance: Results of Intergroup trial S9321. Blood 2003;102:42a (abstract no. 135).
49. 2) versus oral melphalan/prednisolone. Blood 2003;102; 984a (abstract no. 3661).
50. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
51. Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, et al. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Natl Med J India 2003;16:16-21.
52. Mileshkin L, Prince HM. The adverse prognostic impact of advanced age in multiple myeloma. Leak Lymphoma 2005;46:951-66.
53. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600-7.
54. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822-9.
55. Kumar L, Gulati SC. Haematology: Peripheral stem-cell transplantation. Lancet 1995; 346 (Suppl):9.
56. Raje N, Powles R, Horton C, Millar B, Shepherd V, Middleton G, et al. Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer 1997;75:1684-9.
57. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6.
58. International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry (IBMTR/ABMTR) News letter 2000;7:3-10.
59. Blade J, Vesole DH, Gertz M. High-dose therapy in multiple myeloma. Blood 2003;102:3469-70.
60. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-5.
61. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman T, Apperley J, Remes K, et al. 5489 autotransplants in multiple myeloma: A registry from the EBMT. Blood 1999; 94 (Suppl I):714a (abstract).
62. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93:1858-68.
63. Goldschmidt H, Bouko Y, Bourhis JH, Grenix H, Salles G, Derigs G, et al. CD34+ selected PBPCT results in an increased infective risk without prolongation of event-free survival in newly diagnosed myeloma: A randomized study from the EBMT. Blood 2000;96:558a (abstract no. 2396).
64. Blade J, Esteve J. Viewpoint on the impact of interferon in the treatment of multiple myeloma: Benefit for a small proportion of patients? Med Oncol 2000;17:77-84.
65. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502.
66. Sengar M, Kumar L, Ganessan K, Mohanty S, Wadhwa J, Kochupillai V. Role of post transplant maintenance therapy in multiple myeloma: Results from a developing country. Proc Am Soc Clin Oncol 2005;24:6731, 616S (abstract).
67. Bjorkstand B, Hagman A, Ljungman P, Ljungman P, Apperley J, Mandelli F, et al. Autologous stem cell transplantation in multiple myeloma (MM). Bone Marrow Transplant 2001;27:S40.
68. Fermand JP, Alberti C, Marolleau J-P. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: Results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Hematol J 2003;4 (Suppl 1):S59 (abstract).
69. Cavo M, Tosi P, Zamagni E, Celleni C, Ronconi S, De Vivo A, et al. The 'Bologna 96' clinical trial of single vs. double autotransplant for previously untreated multiple myeloma patients. Blood 2002;100:179a (abstract).
70. Goldschmidt H. Single versus double high dose therapy in multiple myeloma: Second analysis of the trial GMMG-HD2 (abstract). Proc Multiple Myeloma 2004 Meeting. Torino, Italy, 22-24 April 2004:119.
71. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood 2003;101:2144-51.
72. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed between 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209-16.
73. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031-7.
74. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000;18: 2273-81.
75. Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-9.
76. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-54.
77. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood 2005;105:4532-9.
78. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430-4.
79. Pulsoni A, Avvisati G, Petrucci MT, Mandelli F, Giannarelli D, Lauta VM, et al. The Italian experience on interferon as maintenance treatment in multiple myeloma: Ten years after. Blood 1998;92:2184-6.
80. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 1994;12:2405-14.
81. Myeloma Trialist's Collaborative Group. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020-34.
82. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
83. Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 2002;13:1636-40.
84. Zangari M, Elice F, Flink L, Anaissie E, Fassas A, Hollmig KA, et al. Thalidomide and cardiovascular complications in multiple myeloma. Hematologica/Hematol J 2005;90 (Suppl 1):8-9 (abstract no. F2.02).
85. Weber D. Lenalidomide (CC-5013, RevlimidTM) and other IMIDS. Hematologica/Hematol J 2005;90 (Suppl 1):25-6.
86. Richardson P, Jagannath S, Schlossman R, Zeldenrust S, Rajkumar SV, Alsina M, et al. A multicenter, randomized phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (dexamethasone) for the treatment of relapsed or relapsed refractory multiple myeloma. Blood 2003;102:235a (abstract no. 825).
87. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
88. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
89. Berenson JR, Boccia R, Bessudo A, Patel R, Steis R, Louie R et al. Arsenic trioxide in refractory or relapsed multiple myeloma: Rationale and clinical efficacy using the MAC regimen. Haematologica/Hematol J 2005;90 (Suppl 1):156.
90. Abou-Jawde R, Reed J, Kelly M, Platt L, Kovak MR, Karam MA, et al. Arsenic trioxide ascorbic acid and dexamethasone pulses for relapsed/ refractory progressive myeloma patients: Long term follow up. Haematologica/Hematol J 2005;90 (Suppl 1):156.
91. Lee KP, NJ Bahlis NJ, McCafferty J, Jordan I, Reis I, Goodman M, et al. Phase I/II trial of arsenic trioxide plus ascorbic acid for relapsed/ refractory multiple myeloma (NCI 43/SCCC 200010): Interim analysis of clinical and laboratory correlates. Haematologica/Hematol J 2005;90 (Suppl 1):155.
92. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
93. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-93.
94. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
95. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002;20:2382-7.
96. Ludwig H. Prevalence, pathogenesis and treatment of anemia with erythropoietic agents in multiple myeloma. Haematologica/Hematol J 2005;90(Suppl 1):16-17.
97. Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol 1998;100:647-54.
98. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood 1999;93:2411-19.
99. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 2000;109:661-4.
100. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and haematopoietic cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30.